Difference between revisions of "Cutaneous basal cell carcinoma"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(added regimen)
m
Line 11: Line 11:
  
 
=Basal cell carcinoma=
 
=Basal cell carcinoma=
−
==Cisplatin (Platinol) & Bleomycin (Blenoxane) {{#subobject:3ba784|Regimen=1}}==
+
==Bleomycin & Cisplatin {{#subobject:3ba784|Regimen=1}}==
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
Line 17: Line 17:
 
|}
 
|}
 
===Regimen {{#subobject:58ad71|Variant=1}}===
 
===Regimen {{#subobject:58ad71|Variant=1}}===
−
Level of Evidence:
+
{| border="1" style="text-align:center;" !align="left"
−
<span  
+
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|-
 +
|[http://journals.lww.com/amjclinicaloncology/pages/articleviewer.aspx?year=1999&issue=02000&article=00008&type=abstract Denic et al. 1999]
 +
|<span  
 
style="background:#ff0000;
 
style="background:#ff0000;
 
padding:3px 6px 3px 6px;
 
padding:3px 6px 3px 6px;
Line 24: Line 28:
 
border-width:2px;
 
border-width:2px;
 
border-style:solid;">Pilot, <20 patients reported</span>
 
border-style:solid;">Pilot, <20 patients reported</span>
 +
|-
 +
|}
  
 
''Neoadjuvant case reports only.''
 
''Neoadjuvant case reports only.''
Line 34: Line 40:
 
# Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999 Feb;22(1):32-4. [http://journals.lww.com/amjclinicaloncology/pages/articleviewer.aspx?year=1999&issue=02000&article=00008&type=abstract link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/10025376 PubMed]
 
# Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999 Feb;22(1):32-4. [http://journals.lww.com/amjclinicaloncology/pages/articleviewer.aspx?year=1999&issue=02000&article=00008&type=abstract link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/10025376 PubMed]
  
−
==Cisplatin (Platinol) & Doxorubicin (Adriamycin) {{#subobject:1ab6f6|Regimen=1}}==
+
==Cisplatin & Doxorubicin {{#subobject:1ab6f6|Regimen=1}}==
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
Line 40: Line 46:
 
|}
 
|}
 
===Regimen {{#subobject:dd241e|Variant=1}}===
 
===Regimen {{#subobject:dd241e|Variant=1}}===
−
Level of Evidence:
+
{| border="1" style="text-align:center;" !align="left"
−
<span  
+
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|-
 +
|[http://jco.ascopubs.org/content/8/2/342.long Guthrie et al. 1990]
 +
|<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
 
padding:3px 6px 3px 6px;
 
padding:3px 6px 3px 6px;
Line 47: Line 57:
 
border-width:2px;
 
border-width:2px;
 
border-style:solid;">Non-randomized</span>
 
border-style:solid;">Non-randomized</span>
 +
|-
 +
|}
  
 
*[[Cisplatin (Platinol)]] 75 mg/m2 IV on day 1
 
*[[Cisplatin (Platinol)]] 75 mg/m2 IV on day 1
Line 58: Line 70:
 
# Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990 Feb;8(2):342-6. [http://jco.ascopubs.org/content/8/2/342.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/2405109 PubMed]
 
# Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990 Feb;8(2):342-6. [http://jco.ascopubs.org/content/8/2/342.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/2405109 PubMed]
  
−
==Cisplatin (Platinol) & Paclitaxel (Taxol) {{#subobject:c1f84a|Regimen=1}}==
+
==Cisplatin & Paclitaxel {{#subobject:c1f84a|Regimen=1}}==
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
Line 64: Line 76:
 
|}
 
|}
 
===Regimen {{#subobject:a20122|Variant=1}}===
 
===Regimen {{#subobject:a20122|Variant=1}}===
−
Level of Evidence:
+
{| border="1" style="text-align:center;" !align="left"
−
<span  
+
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|-
 +
|[http://onlinelibrary.wiley.com/doi/10.1111/j.1445-1433.2004.03130.x/abstract Jefford et al. 2004]
 +
|<span  
 
style="background:#ff0000;
 
style="background:#ff0000;
 
padding:3px 6px 3px 6px;
 
padding:3px 6px 3px 6px;
Line 71: Line 87:
 
border-width:2px;
 
border-width:2px;
 
border-style:solid;">Pilot, <20 patients reported</span>
 
border-style:solid;">Pilot, <20 patients reported</span>
 +
|-
 +
|}
  
 
''Case report only.''
 
''Case report only.''
Line 86: Line 104:
 
|[[#toc|back to top]]
 
|[[#toc|back to top]]
 
|}
 
|}
−
===Regimen, Migden et al. 2015 (BOLT) {{#subobject:PYV1|Variant=1}}===
+
===Regimen {{#subobject:PYV1|Variant=1}}===
−
Level of Evidence:
+
{| border="1" style="text-align:center;" !align="left"
−
<span  
+
|'''Study'''
−
style="background:#EEEE00;
+
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|'''Comparator'''
 +
|-
 +
|[http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2815%2970100-2/fulltext Migden et al. 2015 (BOLT)]
 +
|<span  
 +
style="background:#00cd00;
 
padding:3px 6px 3px 6px;
 
padding:3px 6px 3px 6px;
 
border-color:black;
 
border-color:black;
 
border-width:2px;
 
border-width:2px;
−
border-style:solid;">Phase II</span>
+
border-style:solid;">Randomized Phase II</span>
 +
|Sonidegib 800 mg
 +
|-
 +
|}
  
 
''In Migden et al. 2015 (BOLT), Sonidegib 200 mg was assessed as having a better benefit-to-risk profile than the other tested dose, Sonidegib 800 mg.''
 
''In Migden et al. 2015 (BOLT), Sonidegib 200 mg was assessed as having a better benefit-to-risk profile than the other tested dose, Sonidegib 800 mg.''
−
*[[Sonidegib (Odomzo)]] 200 mg PO daily
+
*[[Sonidegib (Odomzo)]] 200 mg PO once per day
  
 
'''given until progression of disease or unacceptable toxicity'''
 
'''given until progression of disease or unacceptable toxicity'''
  
 
===References===
 
===References===
−
# Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Chang AL, Cornélis F, Lear JT, Sellami D, Dummer R. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015 Jun;16(6):716-28. [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2815%2970100-2/abstract link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/25981810 PubMed]
+
# Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Chang AL, Cornélis F, Lear JT, Sellami D, Dummer R. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015 Jun;16(6):716-28. [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2815%2970100-2/fulltext link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/25981810 PubMed]
  
 
==Vismodegib (Erivedge) {{#subobject:49aef0|Regimen=1}}==
 
==Vismodegib (Erivedge) {{#subobject:49aef0|Regimen=1}}==
Line 109: Line 135:
 
|}
 
|}
 
===Regimen {{#subobject:e5e31b|Variant=1}}===
 
===Regimen {{#subobject:e5e31b|Variant=1}}===
−
Level of Evidence:
+
{| border="1" style="text-align:center;" !align="left"
−
<span  
+
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|-
 +
|[http://www.nejm.org/doi/full/10.1056/NEJMoa1113713 Sekulic et al. 2012]
 +
|<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
 
padding:3px 6px 3px 6px;
 
padding:3px 6px 3px 6px;
Line 116: Line 146:
 
border-width:2px;
 
border-width:2px;
 
border-style:solid;">Non-randomized</span>
 
border-style:solid;">Non-randomized</span>
 +
|-
 +
|}
  
−
*[[Vismodegib (Erivedge)]] 150 mg PO daily
+
*[[Vismodegib (Erivedge)]] 150 mg PO once per day
  
 
===References===
 
===References===
−
# Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, Low JA. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009 Sep 17;361(12):1164-72. Epub 2009 Sep 2. [http://www.nejm.org/doi/full/10.1056/NEJMoa0905360 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19726763 PubMed]
+
# '''Phase I:''' Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, Low JA. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009 Sep 17;361(12):1164-72. Epub 2009 Sep 2. [http://www.nejm.org/doi/full/10.1056/NEJMoa0905360 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19726763 PubMed]
−
# LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011 Apr 15;17(8):2502-11. Epub 2011 Feb 7. [http://clincancerres.aacrjournals.org/content/17/8/2502.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21300762 PubMed]
+
# '''Phase I:''' LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011 Apr 15;17(8):2502-11. Epub 2011 Feb 7. [http://clincancerres.aacrjournals.org/content/17/8/2502.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21300762 PubMed]
 +
# Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012 Jun 7;366(23):2171-9. [http://www.nejm.org/doi/full/10.1056/NEJMoa1113713 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/22670903 PubMed]
  
 
=Squamous cell carcinoma=
 
=Squamous cell carcinoma=
 +
==Bleomycin & Cisplatin {{#subobject:25eb19|Regimen=1}}==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#toc|back to top]]
 +
|}
 +
===Regimen {{#subobject:d4d7f3|Variant=1}}===
 +
{| border="1" style="text-align:center;" !align="left"
 +
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|-
 +
|[http://journals.lww.com/amjclinicaloncology/pages/articleviewer.aspx?year=1999&issue=02000&article=00008&type=abstract Denic et al. 1999]
 +
|<span
 +
style="background:#ff0000;
 +
padding:3px 6px 3px 6px;
 +
border-color:black;
 +
border-width:2px;
 +
border-style:solid;">Pilot, <20 patients reported</span>
 +
|-
 +
|}
 +
 +
''Neoadjuvant case reports only.''
 +
*[[Cisplatin (Platinol)]] 20 mg/m2 IV once per day on days 1 to 4
 +
*[[Bleomycin (Blenoxane)]] 20 mg IV once per day on days 1 to 4
 +
 +
'''21-day cycles x 3 cycles'''
 +
 +
===References===
 +
# Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999 Feb;22(1):32-4. [http://journals.lww.com/amjclinicaloncology/pages/articleviewer.aspx?year=1999&issue=02000&article=00008&type=abstract link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/10025376 PubMed]
 +
 
==Cetuximab (Erbitux) {{#subobject:5f3411|Regimen=1}}==
 
==Cetuximab (Erbitux) {{#subobject:5f3411|Regimen=1}}==
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
Line 129: Line 191:
 
|[[#toc|back to top]]
 
|[[#toc|back to top]]
 
|}
 
|}
−
===Regimen #1, Maubec et al. 2011 {{#subobject:f75d12|Variant=1}}===
+
===Regimen #1 {{#subobject:f75d12|Variant=1}}===
−
Level of Evidence:
+
{| border="1" style="text-align:center;" !align="left"
−
<span  
+
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|-
 +
|[http://jco.ascopubs.org/content/29/25/3419.long Maubec et al. 2011]
 +
|<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
 
padding:3px 6px 3px 6px;
 
padding:3px 6px 3px 6px;
Line 137: Line 203:
 
border-width:2px;
 
border-width:2px;
 
border-style:solid;">Phase II</span>
 
border-style:solid;">Phase II</span>
 +
|-
 +
|}
  
 
*[[Cetuximab (Erbitux)]] 400 mg/m2 IV x 1, then 250 mg/m2 IV once per week
 
*[[Cetuximab (Erbitux)]] 400 mg/m2 IV x 1, then 250 mg/m2 IV once per week
Line 142: Line 210:
 
'''given for at least 6 weeks, to be continued until progression of disease or unacceptable toxicity'''
 
'''given for at least 6 weeks, to be continued until progression of disease or unacceptable toxicity'''
  
−
===Regimen #2, Kim et al. 2011 {{#subobject:7579ab|Variant=1}}===
+
===Regimen #2 {{#subobject:7579ab|Variant=1}}===
−
Level of Evidence:
+
{| border="1" style="text-align:center;" !align="left"
−
<span  
+
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|-
 +
|[http://onlinelibrary.wiley.com/doi/10.1002/hed.21299/abstract Kim et al. 2011]
 +
|<span  
 
style="background:#ff0000;
 
style="background:#ff0000;
 
padding:3px 6px 3px 6px;
 
padding:3px 6px 3px 6px;
Line 150: Line 222:
 
border-width:2px;
 
border-width:2px;
 
border-style:solid;">Pilot, <20 patients reported</span>
 
border-style:solid;">Pilot, <20 patients reported</span>
 +
|-
 +
|}
  
 
''Case report only.''
 
''Case report only.''
 
*[[Cetuximab (Erbitux)]] 400 mg/m2 IV x 1, then 250 mg/m2 IV once per week x 3 months
 
*[[Cetuximab (Erbitux)]] 400 mg/m2 IV x 1, then 250 mg/m2 IV once per week x 3 months
  
−
===Regimen #3, Miller et al. 2010 {{#subobject:608448|Variant=1}}===
+
===Regimen #3 {{#subobject:608448|Variant=1}}===
−
Level of Evidence:
+
{| border="1" style="text-align:center;" !align="left"
−
<span  
+
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|-
 +
|[http://onlinelibrary.wiley.com/doi/10.1111/j.1524-4725.2010.01786.x/abstract Miller et al. 2010]
 +
|<span  
 
style="background:#ff0000;
 
style="background:#ff0000;
 
padding:3px 6px 3px 6px;
 
padding:3px 6px 3px 6px;
Line 162: Line 240:
 
border-width:2px;
 
border-width:2px;
 
border-style:solid;">Pilot, <20 patients reported</span>
 
border-style:solid;">Pilot, <20 patients reported</span>
 +
|-
 +
|}
  
 
''Case report only.''
 
''Case report only.''
Line 172: Line 252:
 
# Suen JK, Bressler L, Shord SS, Warso M, Villano JL. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs. 2007 Aug;18(7):827-9. [http://journals.lww.com/anti-cancerdrugs/pages/articleviewer.aspx?year=2007&issue=08000&article=00011&type=abstract link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/17581306 PubMed]
 
# Suen JK, Bressler L, Shord SS, Warso M, Villano JL. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs. 2007 Aug;18(7):827-9. [http://journals.lww.com/anti-cancerdrugs/pages/articleviewer.aspx?year=2007&issue=08000&article=00011&type=abstract link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/17581306 PubMed]
 
# Arnold AW, Bruckner-Tuderman L, Zuger C, Itin PH. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Dermatology. 2009;219(1):80-3. Epub 2009 May 13. [http://content.karger.com/produktedb/produkte.asp?DOI=10.1159/000218714 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/19439919 PubMed]
 
# Arnold AW, Bruckner-Tuderman L, Zuger C, Itin PH. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Dermatology. 2009;219(1):80-3. Epub 2009 May 13. [http://content.karger.com/produktedb/produkte.asp?DOI=10.1159/000218714 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/19439919 PubMed]
−
# Miller K, Sherman W, Ratner D. Complete clinical response to cetuximab in a patient with metastatic cutaneous squamous cell carcinoma. Dermatol Surg. 2010 Dec;36(12):2069-74. doi: 10.1111/j.1524-4725.2010.01786.x. Epub 2010 Oct 11. [http://onlinelibrary.wiley.com/doi/10.1111/j.1524-4725.2010.01786.x/abstract link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21044226 PubMed] content property of [http://hemonc.org HemOnc.org]  
+
# Miller K, Sherman W, Ratner D. Complete clinical response to cetuximab in a patient with metastatic cutaneous squamous cell carcinoma. Dermatol Surg. 2010 Dec;36(12):2069-74. Epub 2010 Oct 11. [http://onlinelibrary.wiley.com/doi/10.1111/j.1524-4725.2010.01786.x/abstract link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21044226 PubMed] content property of [http://hemonc.org HemOnc.org]  
−
# Kim S, Eleff M, Nicolaou N. Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck. Head Neck. 2011 Feb;33(2):286-8. doi: 10.1002/hed.21299. [http://onlinelibrary.wiley.com/doi/10.1002/hed.21299/abstract link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19953623 PubMed]  
+
# Kim S, Eleff M, Nicolaou N. Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck. Head Neck. 2011 Feb;33(2):286-8. [http://onlinelibrary.wiley.com/doi/10.1002/hed.21299/abstract link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19953623 PubMed]  
 
# Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, Certain A, Duval X, Crickx B, Buffard V, Basset-Seguin N, Saez P, Duval-Modeste AB, Adamski H, Mansard S, Grange F, Dompmartin A, Faivre S, Mentré F, Avril MF. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011 Sep 1;29(25):3419-26. Epub 2011 Aug 1. [http://jco.ascopubs.org/content/29/25/3419.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21810686 PubMed]
 
# Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, Certain A, Duval X, Crickx B, Buffard V, Basset-Seguin N, Saez P, Duval-Modeste AB, Adamski H, Mansard S, Grange F, Dompmartin A, Faivre S, Mentré F, Avril MF. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011 Sep 1;29(25):3419-26. Epub 2011 Aug 1. [http://jco.ascopubs.org/content/29/25/3419.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21810686 PubMed]
  
−
==Cisplatin (Platinol) & Bleomycin (Blenoxane) {{#subobject:25eb19|Regimen=1}}==
+
==Cisplatin & Doxorubicin {{#subobject:ab12b5|Regimen=1}}==
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
 
|[[#toc|back to top]]
 
|[[#toc|back to top]]
 
|}
 
|}
−
===Regimen {{#subobject:d4d7f3|Variant=1}}===
+
===Regimen {{#subobject:f6ac66|Variant=1}}===
−
Level of Evidence:
+
{| border="1" style="text-align:center;" !align="left"
−
<span
+
|'''Study'''
−
style="background:#ff0000;
+
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
−
padding:3px 6px 3px 6px;
 
−
border-color:black;
 
−
border-width:2px;
 
−
border-style:solid;">Pilot, <20 patients reported</span>
 
−
 
 
−
''Neoadjuvant case reports only.''
 
−
*[[Cisplatin (Platinol)]] 20 mg/m2 IV once per day on days 1 to 4
 
−
*[[Bleomycin (Blenoxane)]] 20 mg IV once per day on days 1 to 4
 
−
 
 
−
'''21-day cycles x 3 cycles'''
 
−
 
 
−
===References===
 
−
# Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999 Feb;22(1):32-4. [http://journals.lww.com/amjclinicaloncology/pages/articleviewer.aspx?year=1999&issue=02000&article=00008&type=abstract link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/10025376 PubMed]
 
−
 
 
−
==Cisplatin (Platinol) & Doxorubicin (Adriamycin) {{#subobject:ab12b5|Regimen=1}}==
 
−
{| class="wikitable" style="float:right; margin-left: 5px;"
 
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[http://jco.ascopubs.org/content/8/2/342.long Guthrie et al. 1990]
−
|}
+
|<span  
−
===Regimen {{#subobject:f6ac66|Variant=1}}===
 
−
Level of Evidence:
 
−
<span  
 
 
style="background:#EEEE00;
 
style="background:#EEEE00;
 
padding:3px 6px 3px 6px;
 
padding:3px 6px 3px 6px;
Line 212: Line 273:
 
border-width:2px;
 
border-width:2px;
 
border-style:solid;">Non-randomized</span>
 
border-style:solid;">Non-randomized</span>
 +
|-
 +
|}
  
 
*[[Cisplatin (Platinol)]] 75 mg/m2 IV on day 1
 
*[[Cisplatin (Platinol)]] 75 mg/m2 IV on day 1
Line 223: Line 286:
 
# Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990 Feb;8(2):342-6. [http://jco.ascopubs.org/content/8/2/342.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/2405109 PubMed]
 
# Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990 Feb;8(2):342-6. [http://jco.ascopubs.org/content/8/2/342.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/2405109 PubMed]
  
−
==Interferon alfa-2a (Roferon-A), Isotretinoin, Cisplatin (Platinol) {{#subobject:74bf3|Regimen=1}}==
+
==Cisplatin, Interferon alfa-2a, Isotretinoin {{#subobject:74bf3|Regimen=1}}==
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
Line 229: Line 292:
 
|}
 
|}
 
===Regimen {{#subobject:399afe|Variant=1}}===
 
===Regimen {{#subobject:399afe|Variant=1}}===
−
Level of Evidence:
+
{| border="1" style="text-align:center;" !align="left"
−
<span  
+
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|-
 +
|[http://jco.ascopubs.org/content/20/2/364.long Shin et al. 2002]
 +
|<span  
 
style="background:#EEEE00;
 
style="background:#EEEE00;
 
padding:3px 6px 3px 6px;
 
padding:3px 6px 3px 6px;
Line 236: Line 303:
 
border-width:2px;
 
border-width:2px;
 
border-style:solid;">Phase II</span>
 
border-style:solid;">Phase II</span>
 +
|-
 +
|}
  
 
''Note: Shin et al. 2002 did not clearly specify whether the interferon alfa used in the trial was 2a or 2b, but based on the details in the paper and the references cited, it is inferred that interferon alfa-2a was used.''
 
''Note: Shin et al. 2002 did not clearly specify whether the interferon alfa used in the trial was 2a or 2b, but based on the details in the paper and the references cited, it is inferred that interferon alfa-2a was used.''
 
*[[Interferon alfa-2a (Roferon-A)]] 5,000,000 units/m2 SC 3 times per week
 
*[[Interferon alfa-2a (Roferon-A)]] 5,000,000 units/m2 SC 3 times per week
−
*[[Isotretinoin (Accutane)]] 1 mg/kg PO daily
+
*[[Isotretinoin (Accutane)]] 1 mg/kg PO once per day
 
*[[Cisplatin (Platinol)]] 20 mg/m2 IV once per week
 
*[[Cisplatin (Platinol)]] 20 mg/m2 IV once per week
  
 
===References===
 
===References===
 
# Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, Forastiere AA, Ginsberg L, Liu D, Lee JJ, Myers J, Goepfert H, Lotan R, Hong WK, Lippman SM. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol. 2002 Jan 15;20(2):364-70. [http://jco.ascopubs.org/content/20/2/364.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/11786562 PubMed]
 
# Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, Forastiere AA, Ginsberg L, Liu D, Lee JJ, Myers J, Goepfert H, Lotan R, Hong WK, Lippman SM. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol. 2002 Jan 15;20(2):364-70. [http://jco.ascopubs.org/content/20/2/364.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/11786562 PubMed]

Revision as of 21:38, 31 May 2016

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

6 regimens on this page
7 variants on this page


Basal cell carcinoma

Bleomycin & Cisplatin

back to top

Regimen

Study Evidence
Denic et al. 1999 Pilot, <20 patients reported

Neoadjuvant case reports only.

21-day cycles x 3 cycles

References

  1. Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999 Feb;22(1):32-4. link to original article contains protocol PubMed

Cisplatin & Doxorubicin

back to top

Regimen

Study Evidence
Guthrie et al. 1990 Non-randomized

21-day cycles

References

  1. Guthrie TH, Porubsky ES. Successful systemic chemotherapy of advanced squamous and basal cell carcinoma of the skin with cis-diamminedichloroplatinum III and doxorubicin. Laryngoscope. 1982 Nov;92(11):1298-9. PubMed
  2. Guthrie TH Jr, McElveen LJ, Porubsky ES, Harmon JD. Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer. 1985 Apr 15;55(8):1629-32. PubMed
  3. Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990 Feb;8(2):342-6. link to original article contains verified protocol PubMed

Cisplatin & Paclitaxel

back to top

Regimen

Study Evidence
Jefford et al. 2004 Pilot, <20 patients reported

Case report only.

21-day cycles

References

  1. Jefford M, Kiffer JD, Somers G, Daniel FJ, Davis ID. Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel. ANZ J Surg. 2004 Aug;74(8):704-5. link to original article contains verified protocol PubMed

Sonidegib (Odomzo)

back to top

Regimen

Study Evidence Comparator
Migden et al. 2015 (BOLT) Randomized Phase II Sonidegib 800 mg

In Migden et al. 2015 (BOLT), Sonidegib 200 mg was assessed as having a better benefit-to-risk profile than the other tested dose, Sonidegib 800 mg.

given until progression of disease or unacceptable toxicity

References

  1. Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Chang AL, Cornélis F, Lear JT, Sellami D, Dummer R. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015 Jun;16(6):716-28. link to original article contains verified protocol PubMed

Vismodegib (Erivedge)

back to top

Regimen

Study Evidence
Sekulic et al. 2012 Non-randomized

References

  1. Phase I: Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, Low JA. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009 Sep 17;361(12):1164-72. Epub 2009 Sep 2. link to original article contains verified protocol PubMed
  2. Phase I: LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011 Apr 15;17(8):2502-11. Epub 2011 Feb 7. link to original article contains verified protocol PubMed
  3. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012 Jun 7;366(23):2171-9. link to original article PubMed

Squamous cell carcinoma

Bleomycin & Cisplatin

back to top

Regimen

Study Evidence
Denic et al. 1999 Pilot, <20 patients reported

Neoadjuvant case reports only.

21-day cycles x 3 cycles

References

  1. Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999 Feb;22(1):32-4. link to original article contains protocol PubMed

Cetuximab (Erbitux)

back to top

Regimen #1

Study Evidence
Maubec et al. 2011 Phase II

given for at least 6 weeks, to be continued until progression of disease or unacceptable toxicity

Regimen #2

Study Evidence
Kim et al. 2011 Pilot, <20 patients reported

Case report only.

Regimen #3

Study Evidence
Miller et al. 2010 Pilot, <20 patients reported

Case report only.

6-month cycles, given indefinitely unless progression occurs

References

  1. Bauman JE, Eaton KD, Martins RG. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol. 2007 Jul;143(7):889-92. link to original article PubMed
  2. Suen JK, Bressler L, Shord SS, Warso M, Villano JL. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs. 2007 Aug;18(7):827-9. link to original article PubMed
  3. Arnold AW, Bruckner-Tuderman L, Zuger C, Itin PH. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Dermatology. 2009;219(1):80-3. Epub 2009 May 13. link to original article PubMed
  4. Miller K, Sherman W, Ratner D. Complete clinical response to cetuximab in a patient with metastatic cutaneous squamous cell carcinoma. Dermatol Surg. 2010 Dec;36(12):2069-74. Epub 2010 Oct 11. link to original article contains verified protocol PubMed content property of HemOnc.org
  5. Kim S, Eleff M, Nicolaou N. Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck. Head Neck. 2011 Feb;33(2):286-8. link to original article contains verified protocol PubMed
  6. Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, Certain A, Duval X, Crickx B, Buffard V, Basset-Seguin N, Saez P, Duval-Modeste AB, Adamski H, Mansard S, Grange F, Dompmartin A, Faivre S, Mentré F, Avril MF. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011 Sep 1;29(25):3419-26. Epub 2011 Aug 1. link to original article contains verified protocol PubMed

Cisplatin & Doxorubicin

back to top

Regimen

Study Evidence
Guthrie et al. 1990 Non-randomized

21-day cycles

References

  1. Guthrie TH, Porubsky ES. Successful systemic chemotherapy of advanced squamous and basal cell carcinoma of the skin with cis-diamminedichloroplatinum III and doxorubicin. Laryngoscope. 1982 Nov;92(11):1298-9. PubMed
  2. Guthrie TH Jr, McElveen LJ, Porubsky ES, Harmon JD. Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer. 1985 Apr 15;55(8):1629-32. PubMed
  3. Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990 Feb;8(2):342-6. link to original article contains verified protocol PubMed

Cisplatin, Interferon alfa-2a, Isotretinoin

back to top

Regimen

Study Evidence
Shin et al. 2002 Phase II

Note: Shin et al. 2002 did not clearly specify whether the interferon alfa used in the trial was 2a or 2b, but based on the details in the paper and the references cited, it is inferred that interferon alfa-2a was used.

References

  1. Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, Forastiere AA, Ginsberg L, Liu D, Lee JJ, Myers J, Goepfert H, Lotan R, Hong WK, Lippman SM. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol. 2002 Jan 15;20(2):364-70. link to original article contains verified protocol PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Cutaneous_basal_cell_carcinoma&oldid=11077"